P. Harter

1070P Quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from the PRIMA/ENGOT-OV26/GOG-3012 final analysis

Hannelore Denys, Dana M. Chase, B. Pardo Búrdalo, Sakari Hietanen et autres

be, us, es, fi, it, lu, fr, de, gb (code pays fourni par la source)

LBA44 Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O/ENGOT-ov46/GOG-3025

Carol Aghajanian, Fabian Trillsch, Shin Nishio, June‐Yong Lee et autres

us, de, jp, kr, es, tr, it, fr, fi, pl, at, ca, be, gb (code pays fourni par la source)

84P First results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer

Jacek Grabowski, Elena Ioana Braicu, P. Harter, D. Zocholl et autres

de (code pays fourni par la source)

74MO Prognostic value of PDL1 expression and correlation with HRD status in high-grade serous ovarian cancer: An ancillary analysis of the PAOLA-1/ENGOT-ov25 trial, a GINECO study

I. Treilleux, Stacy Cyrille, Alexis Trécourt, C. Jeanne et autres

fr, lu, it, de, es (code pays fourni par la source)

751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial

Carol Aghajanian, Barbara Schmalfeldt, Aikou Okamoto, JW Kim et autres

us, de, jp, kr, es, tr, it, fr, dk, pl, at, ca, be, sg (code pays fourni par la source)

761P Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies

Bastian Czogalla, Fabian Trillsch, Florian Heitz, Sven Mahner et autres

de, se, fr, dk (code pays fourni par la source)

722P Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial

Laurence Gladieff, J. Martinez-Garcia, Munetaka Takekuma, Guillermo Villacampa et autres

fr, es, jp, us, it, de, se (code pays fourni par la source)

43O Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O

Fabian Trillsch, Aikou Okamoto, JW Kim, M.J. Rubio Pérez et autres

de, jp, kr, es, tr, it, fr, fi, pl, at, ca, nz, be, us (code pays fourni par la source)

Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer

Paul Gaß, Falk C. Thiel, Lothar Häberle, Sven Ackermann et autres

de, at (code pays fourni par la source)

176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

Sakiko Nagao, P. Harter, A. Leary, C. Cropet et autres

jp, de, fr, it, es, at, be, fi (code pays fourni par la source)

Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Isabelle Laure Ray-Coquard, P. Pautier, S. Pignata, D. Pérol et autres